The glymphatic system takes its name from the glial cells that support it, and it was first described as a brain-wide network of perivascular channels along which cerebrospinal fluid flows into brain tissue and interstitial fluid flows out. During sleep, these channels widen and clearance ramps up, carrying away amyloid-beta, tau, and other waste products. In Parkinson’s disease, the pathological hallmark is the accumulation of misfolded alpha-synuclein protein inside neurons, and scientists have long suspected that a failing glymphatic system could allow this protein to accumulate and spread faster, accelerating the disease process. What the new study adds is a direct clinical link: patients whose glymphatic clearance appears most impaired are precisely the ones whose drooling is worst.

To probe that connection, the team enrolled 72 people with Parkinson’s disease, split evenly into 36 patients who experienced drooling and 36 who did not, alongside 38 age-matched healthy controls. Every participant underwent magnetic resonance imaging and a battery of standardized clinical assessments covering disease severity, cognition, mood, and, for the patients with drooling, the severity and frequency of their symptoms using dedicated Parkinson’s-specific scales such as the Sialorrhea Clinical Scale for Parkinson’s disease and the Drooling Severity and Frequency Scale. The design allowed the researchers to compare three groups head to head and to ask which imaging features best separated droolers from non-droolers.

The centerpiece of the imaging analysis was a technique called diffusion tensor image analysis along the perivascular space, abbreviated DTI-ALPS. Diffusion tensor imaging tracks how water molecules diffuse through tissue, and because water moves more freely along the perivascular channels of the glymphatic system than across them, the ALPS index serves as a proxy for how efficiently fluid travels along those clearance routes. A lower ALPS index implies more restricted diffusion along the perivascular spaces, and by inference, more sluggish glymphatic function. The method has been applied in studies of Alzheimer’s disease, normal aging, and sleep disorders, but its use to stratify symptoms within Parkinson’s disease is still relatively novel.

The results were striking. Patients with drooling showed significantly lower ALPS indices on both the left and right hemispheres, as well as a lower bilateral average, than patients without drooling and than the healthy controls. The differences between the drooling and non-drooling Parkinson’s groups reached statistical significance on all three measures, with p values of 0.032 for the left index and 0.004 for both the right index and the bilateral average, while the gap between the drooling group and the healthy controls was even wider, with p values below 0.001 across the board. In other words, among people at the same stage of the same disease, those with drooling carried a distinct and measurable signature of impaired brain fluid dynamics.

The team also examined two other markers of glymphatic health. They measured the volume of the choroid plexus, the vascular tissue in the brain ventricles that produces cerebrospinal fluid, normalized to total intracranial volume. Both Parkinson’s groups, with and without drooling, showed significantly larger choroid plexus volumes relative to healthy controls, with p values of 0.001 and 0.006 respectively, suggesting that choroid plexus enlargement marks the disease itself rather than the drooling symptom specifically. Enlarged perivascular spaces, visible on MRI as dilated fluid-filled channels and another candidate readout of glymphatic drainage, showed no significant differences among the three groups, indicating that this particular structural marker was not sensitive to drooling status in this cohort.

Correlation analyses sharpened the story further. Across the patients, lower ALPS indices were associated with greater overall disease severity and, critically, with more severe drooling symptoms. The researchers then turned to receiver operating characteristic analysis, a standard statistical tool for testing how well a measurement discriminates between two groups, and found that the bilateral average ALPS index was the best single separator of Parkinson’s patients with drooling from those without, achieving an area under the curve of 0.725. A final multivariate logistic regression, which adjusted for other clinical variables, confirmed that the bilateral ALPS index stood as an independent predictor of drooling, with an odds ratio of 0.063 and a 95 percent confidence interval of 0.004 to 0.938 and a p value of 0.045. Because the odds ratio falls below one, it indicates that higher, healthier glymphatic function is associated with lower odds of drooling.

What might connect a brain-wide clearance system to saliva pooling at the corner of the mouth? The authors point to alpha-synuclein. Pathological alpha-synuclein in Parkinson’s disease is not confined to the substantia nigra; it spreads through brainstem and autonomic circuits, including regions that govern swallowing and salivary control. If glymphatic dysfunction permits pathological protein to accumulate more readily in those circuits, the autonomic and motor regulation of swallowing could falter, allowing saliva to collect and spill. The choroid plexus enlargement observed in both patient groups adds a second thread, since the choroid plexus is the source of the cerebrospinal fluid that drives glymphatic flow, and inflammatory or age-related changes in this tissue could compromise the driving pressure of the whole clearance network. The researchers caution that their findings provide indirect, in vivo evidence of this mechanism rather than a direct demonstration, but the concordance between the imaging signal and the clinical symptom is difficult to dismiss.

The practical implications are considerable. Drooling affects a large share of Parkinson’s patients, causing skin irritation around the mouth, increased risk of aspiration and chest infections, and profound embarrassment that leads many people to withdraw from social life. Current treatments, from anticholinergic drugs to botulinum toxin injections into the salivary glands, target the downstream output rather than any upstream neurological cause. If the ALPS index can be validated in larger and more diverse cohorts, it could function as an imaging biomarker that flags patients at risk of developing or worsening drooling, allowing earlier intervention and giving trial designers an objective measure for testing therapies aimed at restoring glymphatic function. The authors suggest that the index may prove useful for predicting both the occurrence and the progression of the symptom over time.

The study has limits that the team acknowledges. With 72 patients drawn from a single center, the cohort is modest, and the cross-sectional design captures a snapshot rather than the arc of disease, so it cannot yet prove that glymphatic decline precedes drooling rather than accompanying it. The ALPS index itself remains an indirect measure, and its interpretation can be influenced by head position, imaging parameters, and age. Even so, the convergence of evidence, from group differences and symptom correlations to independent predictive value in regression, makes a compelling case that the brain’s drainage system matters for one of Parkinson’s most underappreciated symptoms. As glymphatic research moves from animal models toward the clinic, this study signals that waste clearance may hold explanatory power well beyond neurodegeneration itself, reaching into the everyday, embodied symptoms that shape patients’ lives.

Subject of Research: Glymphatic system dysfunction and drooling severity in Parkinson's disease

Article Title: Glymphatic dysfunction predicts drooling severity in Parkinson’s disease

Article References: Glymphatic dysfunction predicts drooling severity in Parkinson’s disease. (n.d.). https://doi.org/10.1186/s12916-026-05299-5

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05299-5

Keywords: Parkinson's disease, glymphatic system, drooling, sialorrhea, DTI-ALPS, MRI biomarker, alpha-synuclein, choroid plexus, perivascular spaces, neurodegeneration, non-motor symptoms, brain clearance